Company profile: Enspire DBS
1.1 - Company Overview
Company description
- Provider of deep brain stimulation (DBS) therapy combined with physical rehabilitation to improve arm motor function in stroke recovery patients, including a clinical trial evaluating DBS safety and effectiveness with therapy and a weekly rehabilitation program as part of the trial.
Products and services
- Clinical Trial for DBS + Rehab: A research-grade study evaluating DBS safety for stroke and effectiveness when combined with structured physical therapy to enhance arm function during recovery
- Deep Brain Stimulation (DBS) Therapy for Stroke Recovery: A clinical-grade therapy integrating DBS with physical rehabilitation to restore motor function, specifically improving arm motor function using a robust method to mediate stimulation and rehabilitation effects
- Weekly Rehabilitation Therapy Program: A protocol-driven weekly program within the clinical trial delivering regular rehabilitation therapy alongside DBS treatment to reinforce arm motor recovery in stroke patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enspire DBS
Labrys Biologics
HQ: United States
Website
- Description: Provider of treatments for chronic migraine, developing RN-307, an antibody for chronic migraine, with worldwide rights acquired from Pfizer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Labrys Biologics company profile →
Atalanta Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology focused on pioneering new treatment options for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atalanta Therapeutics company profile →
Remedy Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remedy Pharmaceuticals company profile →
Jazz Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jazz Pharmaceuticals company profile →
Akome Biotech
HQ: Canada
Website
- Description: Provider of psychedelic-based pharmaceuticals for rare diseases and mental disorders, targeting treatments for cluster headaches, Alzheimer’s disease, and depression, serving patients suffering from stroke and neurological illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akome Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enspire DBS
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enspire DBS
2.2 - Growth funds investing in similar companies to Enspire DBS
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enspire DBS
4.2 - Public trading comparable groups for Enspire DBS
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →